User:Znsila/Scintimammography
 | This is the sandbox page where you will draft your initial Wikipedia contribution.
If you're starting a new article, you can develop it here until it's ready to go live. If you're working on improvements to an existing article, copy only one section at a time of the article to this sandbox to work on, and be sure to use an edit summary linking to the article you copied from. Do not copy over the entire article. You can find additional instructions here. Remember to save your work regularly using the "Publish page" button. (It just means 'save'; it will still be in the sandbox.) You can add bold formatting to your additions to differentiate them from existing content. |
Article Draft
[edit]Molecular Breast Imaging (MBI), also known as scintimammography, is a type of breast imaging test that is used to detect cancer cells in breast tissue of individuals who have had abnormal mammograms, especially for those who have dense breast tissue, post-operative scar tissue or breast implants. [1]
MBI is not used for screening or in place of a mammogram. Rather, it is used when the detection of breast abnormalities is not possible or not reliable on the basis of mammography and ultrasound alone. When mammography plus ultrasound are insufficient to characterize an abnormality, the gold standard next step is Magnetic Resonance Imaging (MRI) of the breast. However, in patients with contraindications (e.g. certain implantable devices) or who prefer to avoid MRI (claustrophobia, discomfort), use of scintimammography is an acceptable alternative.[2][1]
Mechanism
[edit]Scintiamammorgraphy is based on the principle of scintigraphy, where the gamma radiation emitted from injected radiopharmaceuticals is measured by gamma cameras. Cancer cells take up radiopharmaceutical at a higher rate than surrounding normal tissue, and as such they show up on scintigraphy as areas of increases gamma radiation emission. A limitation to this principle is that not all breast lesions with metabolic activity higher than background are cancerous (eg fibroadenoma), and as such judicious use of molecular breast imaging by breast imagers is required.[3]
The most common radiopharmaceutical used in MBI is 99mTc-sestamibi, with doses of 240-300 MBq in current protocols, resulting in an effective dose to a patient of around 2.4 mSv. Earlier iterations of MBI required much higher doses of radiation up to 1100 MBq, which in part led to MBI falling out of favor in the latter part of the last century. However advances in gamma camera technology such as breast specific gamma imaging (BSGI) have allowed for quality resolution at much lower radiation doses, and as such there has been increasing use of MBI.[1][3][4]
Molecular breast imaging added to screening mammogram increases cancer detection rate by about 7-16 positive results per 1000 tests completed, however the dose of radiation experienced by the patient is increased.[1][3][4][5][6]
Procedure
[edit]The procedure is conducted according to practice guidelines corresponding to the region where they are performed (American College of Radiology guidelines in the U.S.). A patient can expect to receive an injection of radiopharmaceutical agent intravenously in the arm contralateral to the breast under investigation. After waiting 5-10 minutes, the breast tissue is placed into the MBI system and a series of images are obtained. Imaging time for both breasts is approximately 40 minutes. For lesions identifiable on MBI but not mammography or ultrasound, MBI guided biopsy is appropriate.[3][7]
Clinical Indications
[edit]Supplemental Screening
[edit]Mammography is widely accepted as the first-line screening option for the detection of breast cancer, with a sensitivity for detection of cancer at around 85-90%. However, in patients with dense breast tissue or those with risk of breast cancer greater than 20%, the sensitivity of mammography drops significantly, with some studies reporting a sensitivity of less than 50%[3]. In these patients, many centers utilize breast ultrasound as additional screening modality, which studies have shown increases breast cancer detection by 2 cancers detected per 1000 people screened.[6] Ultrasound also plays an important role in further characterization of indeterminate lesions seen on screening mammography, but it does result in a significant increase in false positive rate when compared to mammography alone.[6][8] Breast MRI is considered the gold-standard in supplemental imaging of dense breasts, with an increase in cancer detection of about 15 cancers per 1000 screens. In patients where MRI is contraindicated (certain implantable devices, certain kidney conditions) or in those who prefer to avoid MRI (claustrophobia), molecular breast imaging is a viable alternative. MBI has shown to increase detection of breast cancer in dense breasts by 7-16 cancers per 1000 screens.[1][3][5] It is important to keep in mind that MBI does expose patients to radiation, and risk-benefit conversations should be had between physicians and patients prior to use. Discussion in the academic community is ongoing regarding professional recommendations for additional screening in patients with dense breast tissue and in those with increased risk.
References
[edit]- ^ a b c d e Muzahir, Saima (2020-12). "Molecular Breast Cancer Imaging in the Era of Precision Medicine". American Journal of Roentgenology. 215 (6): 1512–1519. doi:10.2214/AJR.20.22883. ISSN 0361-803X.
{{cite journal}}: Check date values in:|date=(help) - ^ Monticciolo, Debra L.; Newell, Mary S.; Moy, Linda; Niell, Bethany; Monsees, Barbara; Sickles, Edward A. (2018-03). "Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR". Journal of the American College of Radiology. 15 (3): 408–414. doi:10.1016/j.jacr.2017.11.034. ISSN 1546-1440.
{{cite journal}}: Check date values in:|date=(help); no-break space character in|title=at position 36 (help) - ^ a b c d e f Patel, Miral M.; Adrada, Beatriz Elena; Fowler, Amy M.; Rauch, Gaiane M. (2023-10). "Molecular Breast Imaging and Positron Emission Mammography". PET Clinics. 18 (4): 487–501. doi:10.1016/j.cpet.2023.04.005. ISSN 1556-8598.
{{cite journal}}: Check date values in:|date=(help) - ^ a b Dibble, Elizabeth H.; Hunt, Katie N.; Ehman, Eric C.; O'Connor, Michael K. (2020-08). "Molecular Breast Imaging in Clinical Practice". American Journal of Roentgenology. 215 (2): 277–284. doi:10.2214/AJR.19.22622. ISSN 0361-803X.
{{cite journal}}: Check date values in:|date=(help) - ^ a b "Molecular Breast Imaging". Society of Nuclear Medicine and Molecular Imaging. Retrieved 15 Oct 2023.
- ^ a b c Huppe, Ashley I.; Mehta, Anita K.; Brem, Rachel F. (2018-02-01). "Molecular Breast Imaging: A Comprehensive Review". Seminars in Ultrasound, CT and MRI. Breast Imaging: State of the Art. 39 (1): 60–69. doi:10.1053/j.sult.2017.10.001. ISSN 0887-2171.
- ^ "ACR Practice Parameter for the Performance of Molecular Breast Imaging (MBI) Using a Dedicated Gamma Camera". 2022. Retrieved Oct 15, 2022.
{{cite web}}: Unknown parameter|authors=ignored (help) - ^ Mann, Ritse M.; Athanasiou, Alexandra; Baltzer, Pascal A. T.; Camps-Herrero, Julia; Clauser, Paola; Fallenberg, Eva M.; Forrai, Gabor; Fuchsjäger, Michael H.; Helbich, Thomas H.; Killburn-Toppin, Fleur; Lesaru, Mihai; Panizza, Pietro; Pediconi, Federica; Pijnappel, Ruud M.; Pinker, Katja (2022-06-01). "Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI)". European Radiology. 32 (6): 4036–4045. doi:10.1007/s00330-022-08617-6. ISSN 1432-1084. PMC 9122856. PMID 35258677.
{{cite journal}}: CS1 maint: PMC format (link)